文献速递细菌感染、耐药与抗菌药物

头孢洛林与头孢吡普对英国和爱尔兰葡萄球菌及肺炎链球菌的活性:BSAC监测数据分析

Activity of ceftaroline versus ceftobiprole against staphylococci and pneumococci in the UK and Ireland: analysis of BSAC surveillance data.
PubMed 文献 · J Antimicrob Chemother · 2020-01-01

该研究基于BSAC耐药监测项目中2008、2013、2017和2018年平行测试的配对数据,比较头孢洛林与头孢吡普对血流葡萄球菌和肺炎链球菌的体外活性。结果显示两者活性相似,头孢洛林MIC多低2倍,MRSA对头孢吡普均敏感,而10/234对头孢洛林仅中介/高剂量敏感。

要点

  • 头孢洛林与头孢吡普对甲氧西林敏感葡萄球菌普遍敏感,MRSA对头孢吡普全部敏感。
  • 10/234 MRSA对头孢洛林仅中介/高剂量敏感,甲氧西林耐药溶血葡萄球菌中65%对头孢吡普耐药。
  • 肺炎链球菌中仅1株对两药均耐药,7株仅对头孢吡普耐药,多属19A/19F血清型。

核心结论

  • 头孢洛林与头孢吡普对葡萄球菌和肺炎链球菌具有相似的的良好活性。
  • 两者之间的治疗选择应基于其他区分因素,包括获批适应证、临床经验和是否需要革兰阴性菌覆盖。

研究设计与样本

  • 基于BSAC耐药监测项目中2008、2013、2017和2018年平行测试的配对结果进行综述。
  • 纳入血流金黄色葡萄球菌1884株(MRSA 234株)、血流CoNS 813株(甲氧西林耐药574株)、血流肺炎链球菌852株和呼吸道肺炎链球菌670株。
  • MIC采用BSAC琼脂稀释法测定,参照EUCAST折点判读,CoNS假定采用金黄色葡萄球菌折点。

主要发现

  • 头孢洛林MIC大多比头孢吡普低2倍,但所有组别中两药MIC均高度相关。
  • 甲氧西林敏感葡萄球菌对两药普遍敏感;所有MRSA对头孢吡普敏感,而10/234对头孢洛林为中介/高剂量敏感。
  • 甲氧西林耐药CoNS中88%对两药敏感,但甲氧西林耐药溶血葡萄球菌中65%出现头孢洛林敏感性降低和头孢吡普耐药。
  • 1株肺炎链球菌对头孢洛林(MIC 0.5 mg/L)和头孢吡普(MIC 1 mg/L)均耐药,另7株仅对头孢吡普耐药(MIC 1 mg/L);这8株中7株属血清型19A或19F。
  • 两种头孢菌素的敏感性均未见时间趋势。

关键数值与推荐

  • MRSA对头孢吡普全部敏感,对头孢洛林10/234为中介/高剂量敏感。
  • 甲氧西林耐药CoNS对两药敏感率为88%,甲氧西林耐药溶血葡萄球菌中65%对头孢吡普耐药。
  • 肺炎链球菌对头孢洛林耐药MIC 0.5 mg/L,对头孢吡普耐药MIC 1 mg/L。

临床怎么用

  • 在覆盖MRSA和肺炎链球菌时,头孢洛林与头孢吡普活性相似,选择需考虑适应证、临床经验及革兰阴性菌覆盖需求。
  • 对甲氧西林耐药溶血葡萄球菌,头孢吡普耐药和头孢洛林敏感性降低较常见,应参考药敏结果。

局限性

  • 仅纳入2008、2013、2017和2018年平行测试的配对数据,非连续年份。
  • CoNS的折点假定采用金黄色葡萄球菌折点,可能影响判读。
  • 未报告具体耐药机制或临床结局数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Ceftaroline and ceftobiprole inhibit most MRSA and MDR pneumococci. Few direct comparisons of their activity have been published, but in several years (2008, 2013, 2017 and 2018) both were tested in parallel in the BSAC Resistance Surveillance Programme, giving paired results. These are reviewed. METHODS: Isolates included were bloodstream Staphylococcus aureus [n = 1884 (MRSA, n = 234)], bloodstream CoNS (n = 813; 574 methicillin resistant), and bloodstream (n = 852) and respiratory (n = 670) Streptococcus pneumoniae. MICs were determined by BSAC agar dilution and reviewed against EUCAST breakpoints; S. aureus breakpoints were assumed for CoNS. RESULTS: Ceftaroline MICs were mostly 2-fold lower than those of ceftobiprole, but, for all groups, MICs of both agents were strongly inter-related. Methicillin-susceptible staphylococci were universally susceptible to both agents; all MRSA were susceptible to ceftobiprole, whereas 10/234 had intermediate/high-dose susceptibility to ceftaroline. Among methicillin-resistant CoNS, 88% were susceptible to both agents, but reduced ceftaroline susceptibility and ceftobiprole resistance were frequent (65%) among methicillin-resistant Staphylococcus haemolyticus. One S. pneumoniae was resistant to both ceftaroline (MIC 0.5 mg/L) and ceftobiprole (MIC 1 mg/L) and seven others were only resistant to ceftobiprole (MIC 1 mg/L); seven of these eight pneumococci belonged to serotype 19A or 19F. No time trend in susceptibility was seen for either cephalosporin. CONCLUSIONS: Ceftaroline and ceftobiprole have similarly good activity against staphylococci and pneumococci. Therapeutic choices between these agents should be predicated on other differentiating factors, including licensed indications, clinical experience and need for Gram-negative coverage.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Horner C, Mushtaq S, Livermore DM, et al. Activity of ceftaroline versus ceftobiprole against staphylococci and pneumococci in the UK and Ireland: analysis of BSAC surveillance data. J Antimicrob Chemother. 2020. PMID: 32728710. doi:10.1093/jac/dkaa306

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。